...in JAMA Network Open, an observational Canadian study ties the antiviral drug combo nirmatrelvir-ritonavir (Paxlovid) to a lower risk of hospitalization or death only in very high-risk COVID-19 patients with weakened immune systems.
A pair of new studies documents initial drops—and, in some cases, rebounds—in cancer diagnoses in Canada and the United States in the first year of the COVID-19 pandemic.
Ottawa's medical officer of health Vera Etches confirmed Thursday these trends will increase in the coming months, but said it's not yet clear that subvariants are driving the surge.
